Effect of n-3 long-chain polyunsaturated fatty acid intake on the eicosanoid profile in individuals with obesity and overweight: a systematic review and meta-analysis of clinical trials

• Published in: Journal of nutritional science (Cambridge) Vol. 10; p. e53
• Main Authors: Schweitzer, Guilherme R. B., Rios, Isabela N. M. S., Gonçalves, Vivian S. S., Magalhães, Kelly G., Pizato, Nathalia
• Format: Journal Article
• Language: English
• Published: Cambridge, UK Cambridge University Press 2021
• Subjects: Arachidonic Acid - blood; Bias; Chronic illnesses; Clinical trials; Clinical Trials as Topic; Eicosanoids; Eicosanoids - blood; Enzymes; Fatty acids; Fatty Acids, Omega-3 - therapeutic use; Gastrointestinal surgery; Human and Clinical Nutrition; Humans; Inflammation; Insulin resistance; Meta-analysis; Metabolism; Metabolites; n-3 PUFA; Obesity; Obesity - blood; Overweight; Overweight - blood; Review; Systematic review; Eicosanoids; Obesity; Systematic review; Inflammation; n-3 PUFA
• ISSN: 2048-6790; 2048-6790
• DOI: 10.1017/jns.2021.46

Dietary n-3 polyunsaturated fatty acids (PUFAs) present beneficial effects on counteracting inflammation status, displaying a critical anti-inflammatory role and maintaining physiological homeostasis in obesity. The primary objective of this systematic review was to evaluate the effect of n-3 PUFAs intake on the eicosanoid profile of people with obesity and overweight. The search strategy on Embase, Scopus, PubMed, Web of Science, Cochrane Library, Google Scholar and ProQuest was undertaken until November 2019 and updated January 2021. The effect size of n-3 PUFAs on prostaglandins was estimated by Glass's, type 1 in a random-effect model for the meta-analysis. Seven clinical trials met the eligible criteria and a total of 610 subjects were included in this systematic review, and four of seven studies were included in meta-analysis. The intake of n-3 PUFAs promoted an overall reduction in serum pro-inflammatory eicosanoids. Additionally, n-3 PUFAs intake significantly decreased the arachidonic acid COX-derived PG eicosanoid group levels (Glass's Δ −0⋅35; CI −0⋅62, −0⋅07, I2 31⋅48). Subgroup analyses showed a higher effect on periods up to 8 weeks (Glass's Δ −0⋅51; CI −0⋅76, −0⋅27) and doses higher than 0⋅5 g of n-3 PUFAs (Glass's Δ −0⋅46; CI −0⋅72, −0⋅27). Dietary n-3 PUFAs intake contributes to reduce pro-inflammatory eicosanoids of people with obesity and overweight. Subgroup's analysis showed that n-3 PUFAs can reduce the overall arachidonic acid COX-derived PG when adequate dose and period are matched.